Molekuláris genetikai módszerek a myeloma multiplex prognózisának megítélésében

Translated title of the contribution: Molecular genetic methods in the prognosis criteria of myeloma multiplex

G. Mikala, János Jákó, István Vályi-Nagy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Routine cytogenetic and molecular genetic analysis of plasma cell malignancies, such as multiple myeloma, became widespread only recently. As the result of these investigations, it became clear that tumor cell karyotype is fundamental from the viewpoint of therapy selection and prognosis. It is worthwhile to distinguish hyperdiploid and nonhyperdiploid myeloma, while five separate prognostic groups (TCI-5) may be identified on the basis of immunoglobulin gene translocations and cyclin expression. Deletion of the q arm of chromosome 13 or amplification of region 1q21 (and the CKS1B gene) can identify further subgroups of poor prognosis and few therapeutic options. Meanwhile, tumors harboring translocation t(11;14) respond favorably to conventional chemotherapy and exhibit exceptionally good and long-lasting response to high-dose chemotherapy. Progression of the disease may coincide with complex translocations of the c-myc gene or deletions involving the p53 tumor-suppressor gene, spreading of ras-mutations. These events represent clonal evolution at great tumor cell mass and advanced disease, therefore, are only of secondary prognostic significance.

Original languageHungarian
Pages (from-to)1673-1682
Number of pages10
JournalOrvosi Hetilap
Volume146
Issue number32
Publication statusPublished - 2005

Fingerprint

Molecular Biology
Neoplasms
Clonal Evolution
Drug Therapy
Chromosomes, Human, Pair 13
Immunoglobulin Genes
myc Genes
Cyclins
Polyploidy
Gene Deletion
Plasma Cells
Tumor Suppressor Genes
Multiple Myeloma
Karyotype
Cytogenetics
Disease Progression
Mutation
Therapeutics
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Molekuláris genetikai módszerek a myeloma multiplex prognózisának megítélésében. / Mikala, G.; Jákó, János; Vályi-Nagy, István.

In: Orvosi Hetilap, Vol. 146, No. 32, 2005, p. 1673-1682.

Research output: Contribution to journalArticle

Mikala, G. ; Jákó, János ; Vályi-Nagy, István. / Molekuláris genetikai módszerek a myeloma multiplex prognózisának megítélésében. In: Orvosi Hetilap. 2005 ; Vol. 146, No. 32. pp. 1673-1682.
@article{42f3d8bad176448db62b8c75a9c4e440,
title = "Molekul{\'a}ris genetikai m{\'o}dszerek a myeloma multiplex progn{\'o}zis{\'a}nak meg{\'i}t{\'e}l{\'e}s{\'e}ben",
abstract = "Routine cytogenetic and molecular genetic analysis of plasma cell malignancies, such as multiple myeloma, became widespread only recently. As the result of these investigations, it became clear that tumor cell karyotype is fundamental from the viewpoint of therapy selection and prognosis. It is worthwhile to distinguish hyperdiploid and nonhyperdiploid myeloma, while five separate prognostic groups (TCI-5) may be identified on the basis of immunoglobulin gene translocations and cyclin expression. Deletion of the q arm of chromosome 13 or amplification of region 1q21 (and the CKS1B gene) can identify further subgroups of poor prognosis and few therapeutic options. Meanwhile, tumors harboring translocation t(11;14) respond favorably to conventional chemotherapy and exhibit exceptionally good and long-lasting response to high-dose chemotherapy. Progression of the disease may coincide with complex translocations of the c-myc gene or deletions involving the p53 tumor-suppressor gene, spreading of ras-mutations. These events represent clonal evolution at great tumor cell mass and advanced disease, therefore, are only of secondary prognostic significance.",
keywords = "Cytogenetic, Immunoglobulin gene, Multiple myeloma, Translocation",
author = "G. Mikala and J{\'a}nos J{\'a}k{\'o} and Istv{\'a}n V{\'a}lyi-Nagy",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "1673--1682",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "32",

}

TY - JOUR

T1 - Molekuláris genetikai módszerek a myeloma multiplex prognózisának megítélésében

AU - Mikala, G.

AU - Jákó, János

AU - Vályi-Nagy, István

PY - 2005

Y1 - 2005

N2 - Routine cytogenetic and molecular genetic analysis of plasma cell malignancies, such as multiple myeloma, became widespread only recently. As the result of these investigations, it became clear that tumor cell karyotype is fundamental from the viewpoint of therapy selection and prognosis. It is worthwhile to distinguish hyperdiploid and nonhyperdiploid myeloma, while five separate prognostic groups (TCI-5) may be identified on the basis of immunoglobulin gene translocations and cyclin expression. Deletion of the q arm of chromosome 13 or amplification of region 1q21 (and the CKS1B gene) can identify further subgroups of poor prognosis and few therapeutic options. Meanwhile, tumors harboring translocation t(11;14) respond favorably to conventional chemotherapy and exhibit exceptionally good and long-lasting response to high-dose chemotherapy. Progression of the disease may coincide with complex translocations of the c-myc gene or deletions involving the p53 tumor-suppressor gene, spreading of ras-mutations. These events represent clonal evolution at great tumor cell mass and advanced disease, therefore, are only of secondary prognostic significance.

AB - Routine cytogenetic and molecular genetic analysis of plasma cell malignancies, such as multiple myeloma, became widespread only recently. As the result of these investigations, it became clear that tumor cell karyotype is fundamental from the viewpoint of therapy selection and prognosis. It is worthwhile to distinguish hyperdiploid and nonhyperdiploid myeloma, while five separate prognostic groups (TCI-5) may be identified on the basis of immunoglobulin gene translocations and cyclin expression. Deletion of the q arm of chromosome 13 or amplification of region 1q21 (and the CKS1B gene) can identify further subgroups of poor prognosis and few therapeutic options. Meanwhile, tumors harboring translocation t(11;14) respond favorably to conventional chemotherapy and exhibit exceptionally good and long-lasting response to high-dose chemotherapy. Progression of the disease may coincide with complex translocations of the c-myc gene or deletions involving the p53 tumor-suppressor gene, spreading of ras-mutations. These events represent clonal evolution at great tumor cell mass and advanced disease, therefore, are only of secondary prognostic significance.

KW - Cytogenetic

KW - Immunoglobulin gene

KW - Multiple myeloma

KW - Translocation

UR - http://www.scopus.com/inward/record.url?scp=26944467998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944467998&partnerID=8YFLogxK

M3 - Article

C2 - 16149245

AN - SCOPUS:26944467998

VL - 146

SP - 1673

EP - 1682

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 32

ER -